NeoGenomics (NG9) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NG9 Analyst Ratings

Moderate Buy

4 Buy

3 Hold

0 Sell

Based on 7 analysts giving stock ratings to

NeoGenomics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NG9 Stock 12 Month Forecast

Average Price Target

€15.54

▲(25.73% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for NeoGenomics in the last 3 months. The average price target is €15.54 with a high forecast of €16.59 and a low forecast of €13.97. The average price target represents a 25.73% change from the last price of €12.36.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"€3","10":"€10","17":"€17","6.5":"€6.5","13.5":"€13.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16.58833779,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€16.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.540653297999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€15.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.96912656,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€13.97</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,6.5,10,13.5,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.595,12.902179830000001,13.20935966,13.516539490000001,13.82371932,14.130899150000001,14.43807898,14.745258810000001,15.05243864,15.359618470000001,15.6667983,15.97397813,16.28115796,{"y":16.58833779,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.595,12.821588715230769,13.04817743046154,13.274766145692308,13.501354860923078,13.727943576153846,13.954532291384615,14.181121006615385,14.407709721846153,14.634298437076922,14.860887152307692,15.08747586753846,15.31406458276923,{"y":15.540653297999999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.595,12.700702043076923,12.806404086153847,12.91210612923077,13.017808172307692,13.123510215384616,13.229212258461539,13.334914301538461,13.440616344615384,13.546318387692308,13.65202043076923,13.757722473846153,13.863424516923077,{"y":13.96912656,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.35,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.606,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.926,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.595,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€16.59

Average Price Target€15.54

Lowest Price Target€13.97

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Matson

Needham

€13.1→€16.59

Buy

34.21%

Upside

Assigned

07/29/26

Analysts Offer Insights on Healthcare Companies: Novartis (NYSE: NVS) and NeoGenomics (NASDAQ: NEO)

Matt Larew

William Blair

―

Hold

―

Reiterated

07/29/26

NeoGenomics: Strong NGS-Driven Momentum Offsetting Strategic and Valuation Concerns, Justifying a Hold Rating

Matt Hewitt

Craig-Hallum

€14.84→€16.59

Buy

34.21%

Upside

Reiterated

07/29/26

NeoGenomics price target raised to $19 from $17 at Craig-HallumNeoGenomics price target raised to $19 from $17 at Craig-Hallum

Daniel Brennan

TD Cowen

€16.59

Buy

34.21%

Upside

Reiterated

07/28/26

Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), NeoGenomics (NEO)

Mark Massaro

BTIG

―

Hold

―

Reiterated

07/28/26

NeoGenomics: Solid Clinical Growth and Guidance Raise Offset by Biopharma Weakness, Keeping Risk‑Reward Balanced at Hold

Bruce Jackson

Benchmark Co.

€9.6→€13.97

Buy

13.02%

Upside

Reiterated

07/24/26

NeoGenomics price target raised to $16 from $11 at BenchmarkNeoGenomics price target raised to $16 from $11 at Benchmark

Michael Ryskin

Bank of America Securities

€9.6→€13.97

Hold

13.02%

Upside

Reiterated

07/13/26

Bank of America Securities Reaffirms Their Hold Rating on NeoGenomics (NEO)

David Westenberg

Piper Sandler

€11.35

Buy

-8.17%

Downside

Reiterated

04/30/26

Piper Sandler Keeps Their Buy Rating on NeoGenomics (NEO)

Unknown Analyst

Stephens

Not Ranked

Stephens

€13.53

Buy

9.49%

Upside

Reiterated

04/29/26

NeoGenomics (NEO) Receives a Buy from Stephens

Puneet Souda

Leerink Partners

€21.83

Buy

76.59%

Upside

Upgraded

04/29/26

NeoGenomics upgraded to Outperform from Market Perform at LeerinkNeoGenomics upgraded to Outperform from Market Perform at Leerink

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€13.1

Buy

5.96%

Upside

Reiterated

02/18/26

Jefferies Sticks to Their Buy Rating for NeoGenomics (NEO)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

02/17/26

NeoGenomics (NEO) Receives a Hold from Guggenheim

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Matson

Needham

€13.1→€16.59

Buy

34.21%

Upside

Assigned

07/29/26

Analysts Offer Insights on Healthcare Companies: Novartis (NYSE: NVS) and NeoGenomics (NASDAQ: NEO)

Matt Larew

William Blair

―

Hold

―

Reiterated

07/29/26

NeoGenomics: Strong NGS-Driven Momentum Offsetting Strategic and Valuation Concerns, Justifying a Hold Rating

Matt Hewitt

Craig-Hallum

€14.84→€16.59

Buy

34.21%

Upside

Reiterated

07/29/26

NeoGenomics price target raised to $19 from $17 at Craig-HallumNeoGenomics price target raised to $19 from $17 at Craig-Hallum

Daniel Brennan

TD Cowen

€16.59

Buy

34.21%

Upside

Reiterated

07/28/26

Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), NeoGenomics (NEO)

Mark Massaro

BTIG

―

Hold

―

Reiterated

07/28/26

NeoGenomics: Solid Clinical Growth and Guidance Raise Offset by Biopharma Weakness, Keeping Risk‑Reward Balanced at Hold

Bruce Jackson

Benchmark Co.

€9.6→€13.97

Buy

13.02%

Upside

Reiterated

07/24/26

NeoGenomics price target raised to $16 from $11 at BenchmarkNeoGenomics price target raised to $16 from $11 at Benchmark

Michael Ryskin

Bank of America Securities

€9.6→€13.97

Hold

13.02%

Upside

Reiterated

07/13/26

Bank of America Securities Reaffirms Their Hold Rating on NeoGenomics (NEO)

David Westenberg

Piper Sandler

€11.35

Buy

-8.17%

Downside

Reiterated

04/30/26

Piper Sandler Keeps Their Buy Rating on NeoGenomics (NEO)

Unknown Analyst

Stephens

Not Ranked

Stephens

€13.53

Buy

9.49%

Upside

Reiterated

04/29/26

NeoGenomics (NEO) Receives a Buy from Stephens

Puneet Souda

Leerink Partners

€21.83

Buy

76.59%

Upside

Upgraded

04/29/26

NeoGenomics upgraded to Outperform from Market Perform at LeerinkNeoGenomics upgraded to Outperform from Market Perform at Leerink

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€13.1

Buy

5.96%

Upside

Reiterated

02/18/26

Jefferies Sticks to Their Buy Rating for NeoGenomics (NEO)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

02/17/26

NeoGenomics (NEO) Receives a Hold from Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NeoGenomics

3 Months

Bruce JacksonBenchmark Co.

Success Rate

9/18 ratings generated profit

Average Return

+2.04%

Copying Bruce Jackson's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +2.04% per trade.

1 Year

David WestenbergPiper Sandler

Success Rate

12/21 ratings generated profit

Average Return

+20.17%

Copying David Westenberg's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +20.17% per trade.

2 Years

Daniel BrennanTD Cowen

Success Rate

12/21 ratings generated profit

Average Return

+21.14%

Copying Daniel Brennan's trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +21.14% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NG9 Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NG9 has received 7 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. NG9 average Analyst price target in the past 3 months is 15.54.

Each month's total comprises the sum of three months' worth of ratings.

NG9 Financial Forecast

NG9 Earnings Forecast

Next quarter’s earnings estimate for NG9 is €0.05 with a range of €0.03 to €0.06. The previous quarter’s EPS was €0.04. NG9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 41.04% of the time in the same period. In the last calendar year NG9 has Performed in-line its overall industry.

NG9 Sales Forecast

Next quarter’s sales forecast for NG9 is €178.69M with a range of €176.96M to €179.26M. The previous quarter’s sales results were €175.01M. NG9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.07% of the time in the same period. In the last calendar year NG9 has Performed in-line its overall industry.

NG9 Stock Forecast FAQ

What is DE:NG9’s average 12-month price target, according to analysts?

Based on analyst ratings, NeoGenomics’s 12-month average price target is 15.54.

What is DE:NG9’s upside potential, based on the analysts’ average price target?

NeoGenomics has 25.73% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NeoGenomics a Buy, Sell or Hold?

NeoGenomics has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 3 hold ratings and 0 sell ratings.

What is NeoGenomics’s share price target?

The average share price target for NeoGenomics is 15.54. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €16.59 ,and the lowest forecast is €13.97. The average share price target represents 25.73% Increase from the current price of €12.36.

What do analysts say about NeoGenomics?

NeoGenomics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of NeoGenomics?

To buy shares of DE:NG9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

NeoGenomics (NG9) Stock Forecast & Price Target

NG9 Analyst Ratings

NG9 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering NeoGenomics

NG9 Analyst Recommendation Trends

NG9 Financial Forecast

NG9 Earnings Forecast

NG9 Sales Forecast

NG9 Stock Forecast FAQ

Detailed List of Analyst Forecasts